{"denoms":[{"counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"23"}],"units":"Participants"}],"groups":[{"description":"Vandetanib 300 mg/day oral","id":"BG000","title":"Vandetanib"},{"description":"Vinorelbine 30 mg/m2 iv, administrated weekly","id":"BG001","title":"Vinorelbine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"54","upperLimit":"77","value":"67"},{"groupId":"BG001","lowerLimit":"27","upperLimit":"76","value":"64"},{"groupId":"BG002","lowerLimit":"27","upperLimit":"77","value":"65.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"22"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}